Welcome to our dedicated page for Eyenovia news (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia stock.
Eyenovia, Inc. (EYEN), which has adopted the corporate name Hyperion DeFi, Inc., generates news that spans both ophthalmic technology and digital asset markets. Company announcements describe a dual focus: development and commercialization of advanced topical eye treatments using its proprietary Optejet dispensing platform, and the build-out of a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain.
On this news page, readers can follow updates on Eyenovia’s transition to Hyperion DeFi, including the reported name change and anticipated ticker change from EYEN to HYPD on the Nasdaq Capital Market. Releases detail the company’s private placement financing to acquire HYPE, launch of a co-branded Hyperliquid validator with Kinetiq, and broader onchain engagement strategy, including staking and validator operations supported by infrastructure provider Pier Two.
Investors and observers can also review ophthalmic-focused news, such as progress reports on the Optejet User Filled Device (UFD), verification and validation milestones, and plans for regulatory submissions. Additional items include updates on potential strategic transactions, such as a contemplated reverse merger with Betaliq, as well as information on existing FDA-approved products like clobetasol propionate ophthalmic suspension, 0.05% and Mydcombi for mydriasis.
Together, these news items provide insight into how the company is combining an ophthalmic technology platform with a cryptocurrency treasury reserve strategy centered on HYPE. For users tracking EYEN, this page offers a consolidated view of corporate actions, financing developments, product updates and blockchain-related initiatives described by the company in its press releases.
Eyenovia (NASDAQ: EYEN) reported its Q1 2024 financial results and updates on key products. The company aims to accelerate the development of MicroPine, a late-stage product for pediatric progressive myopia, and anticipates a 3Q 2024 launch for clobetasol propionate ophthalmic suspension, a new steroid for post-ocular surgery inflammation and pain. Additionally, Eyenovia has trained and shipped products to 50 new Mydcombi-using offices since April 2024.
Financially, the company reported a net loss of $10.9 million or $0.23 per share, compared to a $5.7 million loss or $0.15 per share in Q1 2023. Operating expenses increased by 88.1% year-over-year, partly due to reacquiring MicroPine license rights. Eyenovia reduced anticipated cash-based expenses by $0.8 million per quarter and had $8.0 million in cash and equivalents as of March 31, 2024.
The company has completed manufacturing capabilities with FDA approval for three facilities. A conference call and webcast are scheduled for May 15, 2024, at 4:30 pm ET.
Eyenovia (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, will report its Q1 2024 financial results on May 15, 2024, after the market closes.
A conference call and webcast will follow at 4:30 p.m. ET to review the financial and operating results. Participants can join the call at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Live and archived webcasts will be available on the investor relations page of Eyenovia's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.